Tags : Delivery

Biotech

ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for

Shots: The companies collaborated to develop and commercialize novel in vivo delivery of CRISPR/Cas9 using ProBioGen’s technology. CRISPR Therapeutics also holds an option to license the developed product The focus of the agreement is to expand CRISPR Therapeutics’ in vivo delivery technology in fields of hemoglobinopathies, oncology, regenerative medicine and rare diseases CRISPR Therapeutics’ CRISPR/Cas9 […]Read More